Post-Operative Atrial Fibrillation after Surgical Aortic Valve Replacementand the influence of HMG-CoA reductase inhibitors - STARC210421

Odense University Hospital0 个研究点目标入组 366 人开始时间: 2024年2月27日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Trial 1: Patients undergoing elective solitary SAVR with bioprosthesis; Patients who are in sinus rhythm and not taking any anti-arrhythmic medication; other than beta-adrenergic blocking agents; at the time of surgery; No prior use of statin the last 3 months and at least 7 days prior to the time of surgery Age >60 years; Willingness and provision of informed consent to be randomized. Trial 2: Patients undergoing elective solitary SAVR with bioprosthesis; Patients who are in sinus rhythm and not taking any anti-arrhythmic medication other than beta-adrenergic blocking agents, at the time of surgery; In treatment with statin in the past 3 months and of at least 7 days Age >60 years; Willingness and provision of informed consent to be randomized.

•Prior history of atrial fibrillation; Prior history of cardiac surgery; Known adverse reaction to statin; Hepatic dysfunction (Alanin-aminotransferase more than twice the upper limit); Creatinine >200 µmol/L; Known intolerance to statins or history of muscle toxicity with statins.

发起方